GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new ...
MLIP calculations successfully identify suitable dopants for a novel photocatalytic material, report researchers from the ...
Full year 2025 revenue of $71.7 million, up 40%Record full-year operating cash flow of $13.1 million, up 60%Board ...
Yarilet Perez is an experienced multimedia journalist and fact-checker with a Master of Science in Journalism. She has worked in multiple cities covering breaking news, politics, education, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results